Zacks Research Has Positive Outlook for STERIS Q3 Earnings

STERIS plc (NYSE:STE) – Research analysts at Zacks Research lifted their Q3 2025 earnings estimates for shares of STERIS in a research report issued on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.30 per share for the quarter, up from their previous estimate of $2.29. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.07 EPS, Q1 2026 earnings at $2.25 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.92 EPS, Q1 2027 earnings at $2.47 EPS and FY2027 earnings at $10.25 EPS.

STE has been the subject of a number of other research reports. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. KeyCorp raised their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and a consensus price target of $262.50.

STERIS Price Performance

NYSE STE opened at $207.98 on Friday. The stock has a market capitalization of $20.53 billion, a price-to-earnings ratio of 47.48 and a beta of 0.83. STERIS has a 1-year low of $197.82 and a 1-year high of $248.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. The business’s fifty day moving average price is $217.14 and its 200-day moving average price is $225.99.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The firm had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the previous year, the company earned $2.03 earnings per share. The firm’s quarterly revenue was up 7.3% on a year-over-year basis.

Hedge Funds Weigh In On STERIS

A number of hedge funds have recently made changes to their positions in STE. West Coast Financial LLC lifted its holdings in STERIS by 2.8% in the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock worth $398,000 after purchasing an additional 45 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in shares of STERIS by 1.6% in the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after buying an additional 51 shares in the last quarter. Waterloo Capital L.P. boosted its position in shares of STERIS by 3.2% during the second quarter. Waterloo Capital L.P. now owns 1,916 shares of the medical equipment provider’s stock worth $421,000 after acquiring an additional 59 shares during the last quarter. Metis Global Partners LLC grew its stake in STERIS by 1.6% during the third quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $1,322,000 after acquiring an additional 84 shares in the last quarter. Finally, Insigneo Advisory Services LLC increased its holdings in STERIS by 6.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $409,000 after acquiring an additional 95 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Insiders Place Their Bets

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.14% of the company’s stock.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.10%. The ex-dividend date of this dividend was Tuesday, November 19th. STERIS’s dividend payout ratio is currently 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.